Travere Therapeutics, Inc.

We are aware that certain stockholders and proxy advisory firms have voting policies regarding the number of public company boards on which an executive officer may serve, and that Dr. Baynes currently serves on four public company boards while also serving as Chief Medical Officer of Eikon Therapeutics, Inc., which became a public company following its initial public offering in February 2026.

In considering the re-election of Dr. Baynes at this annual meeting, our Board of Directors evaluated his commitments and determined that he continues to effectively serve the Board and the Company. In reaching this conclusion, the Board considered his significant expertise in clinical development and experience in the development strategy for numerous important medicines, his consistently strong attendance record

(approximately 97% over his tenure), and the valuable leadership and mentorship he provides as Chair of our Science & Technology Committee. The Board will continue to monitor his commitments.